We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AngioDynamics (ANGO) Banks on Buyouts, Debt Level High
Read MoreHide Full Article
On Jan 23, we issued an updated research report on AngioDynamics Inc. (ANGO - Free Report) . The stock has a Zacks Rank #3 (Hold).
AngioDynamics recently reported a dismal second quarter of fiscal 2018, with adjusted earnings and revenues missing the Zacks Consensus Estimate. The slashed guidance for fiscal 2018 sales is also discouraging.
AngioDynamics’ Peripheral Vascular segment has been weak of late. The company also had a high debt level at the end of the last quarter. AngioDynamics’ rising debts impose certain operating and financial restrictions, which limit the company’s execution of core business strategies. The company also recently recalled the Acculis Microwave Tissue Ablation System.
Coming to the stock’s price performance, AngioDynamics saw a negative return of almost 0.6% over the last year, significantly underperforming the S&P 500’s 24.7% gain. Furthermore, the current level compares unfavorably with the broader industry’s gain of 33.6%.
On the flip side, AngioDynamics continues to expand its business on the back of acquisitions and strategic alliances. Major buyouts like Microsulis, Navilyst, Vortex Medical, NanoKnife and RITA Medical have significantly expanded its product pipeline. AngioDynamics has been making disciplined investments across all three of its business segments to drive long-term revenue growth.
AngioDynamics has been offering a broad spectrum of products which has helped widen its commercial opportunities. The company is also a leading player in the thrombolytic catheters space. It has a broad range of unique catheters like Uni-Fuse, SpeedLyser and Pulse Spray under the thrombus portfolio.
AngioDynamics is expected to benefit from the ongoing market transition toward less-invasive interventional procedures. We expect this trend to continue, as less-invasive interventional procedures help reduce patient recovery time, thereby saving hospitalization costs.
Key Picks
A few better-ranked stocks in the broader medical sector are Amedisys (AMED - Free Report) , Bio-Rad Laboratories (BIO - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Amedisys has a long-term expected earnings growth rate of 18.5%. The stock carries a Zacks Rank #2 (Buy).
Intuitive Surgical has a long-term expected earnings growth rate of 10.7%. The stock carries a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
AngioDynamics (ANGO) Banks on Buyouts, Debt Level High
On Jan 23, we issued an updated research report on AngioDynamics Inc. (ANGO - Free Report) . The stock has a Zacks Rank #3 (Hold).
AngioDynamics recently reported a dismal second quarter of fiscal 2018, with adjusted earnings and revenues missing the Zacks Consensus Estimate. The slashed guidance for fiscal 2018 sales is also discouraging.
AngioDynamics’ Peripheral Vascular segment has been weak of late. The company also had a high debt level at the end of the last quarter. AngioDynamics’ rising debts impose certain operating and financial restrictions, which limit the company’s execution of core business strategies. The company also recently recalled the Acculis Microwave Tissue Ablation System.
Coming to the stock’s price performance, AngioDynamics saw a negative return of almost 0.6% over the last year, significantly underperforming the S&P 500’s 24.7% gain. Furthermore, the current level compares unfavorably with the broader industry’s gain of 33.6%.
On the flip side, AngioDynamics continues to expand its business on the back of acquisitions and strategic alliances. Major buyouts like Microsulis, Navilyst, Vortex Medical, NanoKnife and RITA Medical have significantly expanded its product pipeline. AngioDynamics has been making disciplined investments across all three of its business segments to drive long-term revenue growth.
AngioDynamics has been offering a broad spectrum of products which has helped widen its commercial opportunities. The company is also a leading player in the thrombolytic catheters space. It has a broad range of unique catheters like Uni-Fuse, SpeedLyser and Pulse Spray under the thrombus portfolio.
AngioDynamics is expected to benefit from the ongoing market transition toward less-invasive interventional procedures. We expect this trend to continue, as less-invasive interventional procedures help reduce patient recovery time, thereby saving hospitalization costs.
Key Picks
A few better-ranked stocks in the broader medical sector are Amedisys (AMED - Free Report) , Bio-Rad Laboratories (BIO - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Bio-Rad Laboratories flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The company has a long-term expected earnings growth rate of 25%.
Amedisys has a long-term expected earnings growth rate of 18.5%. The stock carries a Zacks Rank #2 (Buy).
Intuitive Surgical has a long-term expected earnings growth rate of 10.7%. The stock carries a Zacks Rank #2.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>